Antibody-Cytokine Combinations With Philogen's Dr. Dario Neri
Business Of Biotech
00:00
How Do You Balance That Line as a Business Leader?
The more collaborative interest there is, i would think, the more opportunity there might be to sort of derail the he and goal of taking a proprietary candidate all the way to the commercial finish line. If what is best for the product is to have a strong commercial partner with a track record in a given indication, that is wi a good strategy. But if we believe that our products are good, and we have to make the next step in the growth of the company, which is really become a full integrated company, then then we will take this challenge.
Transcript
Play full episode
